Pharmaceutical organizations have a problem – there is a growing volume of safety data in varied data sources, report types, formats, etc. This is leading to unsustainable increases in the costs of safety operations and safety assessment, and leaders are looking for innovative solutions from new AI, automation and cloud approaches. A recent Gartner reported stated: "By 2023, 60% of the top 100 life science companies will use AI augmentation in one or more safety vigilance solutions".*
Many of our customers are using the power of IQVIA's Natural Language Processing (NLP) platform from Linguamatics, to optimize their safety processes, and lower development costs. NLP transforms unstructured text into structured data that can be rapidly analyzed or visualized. This capability can be applied for safety assessment and medical review, enabling effective search of literature, drug labels and regulatory review packages for adverse events and the critical context around these, to help with a deeper understanding and contextualization of any potential safety signal.
This webinar will present an overview of customer success stories, and a demo of IQVIA's NLP Insights Hub for safety, to show best practice use of NLP to advance drug safety.
Jane Reed
Director of Life Science Linguamatics, an IQVIA company
Sridevi Krishnamurhy
Application Scientist Linguamatics, an IQVIA company
*Jeff Smith, "Life Science CIOs Reduce Runaway Costs with Innovative Safety Vigilance Technology". March 2021